Mean platelet volume: a useful marker of inflammatory bowel disease activity

Abstract

OBJECTIVES: We investigated whether the mean platelet volume would be a useful marker in the evaluation of inflammatory bowel disease activity. METHODS: Complete blood count, C-reactive protein, erythrocyte sedimentation rate, serum thrombopoietin and erythropoietin, plasma β-thromboglobulin, and platelet factor 4 were measured in 93 patients with ulcerative colitis, 66 patients with Crohn’s disease, and 38 healthy blood donors. Disease activity was assessed by the Clinical Colitis Activity Index in patients with ulcerative colitis and by the Crohn’s Disease Activity Index in patients with Crohn’s disease. RESULTS: Mean platelet count was increased in patients with active compared to inactive ulcerative colitis ( p < 0.05), and in patients with active compared to inactive Crohn’s disease ( p = 0.0002) or healthy controls ( p < 0.0001). On the other hand, mean platelet volume was significantly decreased in patients with active compared to inactive ulcerative colitis ( p = 0.02) or healthy controls ( p < 0.0001), and in patients with active compared to inactive Crohn’s disease ( p = 0.0005) or healthy controls ( p < 0.0001). Mean platelet volume was inversely correlated with the white blood cell count (r = −0.17, p = 0.02), C-reactive protein (r = −0.46, p = 0.009) and erythrocyte sedimentation rate (r = −0.28, p = 0.008). No significant correlations were found between mean platelet volume and serum thrombopoietin or erythropoietin levels; however, a strong negative correlation between mean platelet volume and β-thromboglobulin (r = −0.34, p < 0.0001) and platelet factor 4 (r = −0.30, p = 0.0002) was observed. CONCLUSIONS: Mean platelet volume is significantly reduced in active inflammatory bowel disease and is negatively correlated with the known inflammatory bowel disease activity markers and the platelet activation products. We propose that mean platelet volume provides a useful marker of activity in inflammatory bowel disease.